Abilify (aripiprazole), 5 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC... — FDA record D-0466-2024

Reported ongoing

Status as reported in the agency record. FDA warns that enforcement status may not track the current recall lifecycle; check the current official notice.

Source date Apr 9, 2024. Retrieved Oct 1, 2026. Last updated Oct 1, 2026.

Archive changed Oct 1, 2026. USDA FSIS records are unavailable; check FSIS directly. Source coverage and dates.

What the record says

Product
Abilify (aripiprazole), 5 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-007-13
Reason
Cross Contamination with Other Products
Classification
Class III
Recalling firm
Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.
Quantity
108,192/30 count bottles or 7 count blister packs
Agency-reported status
Ongoing
Source record identifier
D-0466-2024

Open the official record

What the recall classes mean. Classification is an agency assessment, not individual medical advice.

Lot and product identifiers

Label fieldDetails supplied by the agency
Lot, code or applicabilityLot # AKS00623A, Exp 01/31/2026; AKS00322A, Exp 02/28/2025

Match all identifying details in the current notice. A brand name alone is not enough.

Distribution

USA nationwide.

States below are derived from the distribution text, including nationwide wording. They are not inferred from the firm's address.

Dates in the source

Report date
May 1, 2024
Recall initiation date
Apr 9, 2024
Center classification date
Apr 23, 2024

FDA company pages use the listing date; enforcement records use initiation dates; CPSC uses recall date; NHTSA uses report-received date. These dates are not interchangeable.

Related records